
Mintz Adds Patent Litigator for Drug Disputes
Roberts brings Hatch-Waxman and PTAB experience to a growing life sciences patent team in New York.
Live Poll
Do you trust large law firms to serve ordinary people fairly?
This page covers gene editing, drug development, genomics and the intersection of biology and technology in New York City. Reporting follows clinical trials, commercial findings and the growth of research firms across the city.

Roberts brings Hatch-Waxman and PTAB experience to a growing life sciences patent team in New York.
Live Poll
Do you trust large law firms to serve ordinary people fairly?
October 27, 2026
Rumi Therapeutics Licenses New Fragile X Drug CandidateThe firm now holds rights to an IND-ready PDE2 inhibitor intended to address synaptic plasticity in patients.
October 14, 2026
Neion Bio Partnered to Monitor Flock HealthNew York-based Neion Bio integrated Barnwell Bio’s metagenomic surveillance to improve recombinant protein production.
October 13, 2026
Wave Life Sciences to Join RNA Therapeutics PanelThe company will discuss the trajectory of next-generation RNA medicine at a conference in New York City on October 20.
October 13, 2026
National Cancer Institute Awarded Envisagenics $2 MillionThe two-year grant supports the development of an AI-driven machine learning algorithm for cancer therapy discovery.
October 10, 2026
Nuvectis Pharma to Join Maxim Growth Summit PanelThe clinical-stage biotech will discuss advancements in immunology and inflammation therapies on October 14, 2026.
October 10, 2026
Filana Therapeutics Will Attend 2026 Maxim Growth SummitManagement from the epilepsy research firm will participate in one-on-one meetings in New York City this October.
October 6, 2026
Seth Flaum Joined McDermott Will & EmeryThe health and life sciences veteran moves to the firm's New York practice.
October 6, 2026
MediciNova Will Attend Maxim Growth Summit in OctoberThe biopharmaceutical firm will discuss its development pipeline with investors in New York City.
October 5, 2026
4D Molecular Therapeutics Will Host Investor Day October 21The biotech firm will detail progress on its late-stage retinal and respiratory gene therapy programs.
September 30, 2026
Sol-Gel Will Host Gorlin Syndrome Investor Event Oct 14The company will discuss the therapeutic potential and safety profile of SGT-610 in a presentation to investors.
This section follows research findings, clinical trial results, regulatory pathways, venture funding and startup developments. Coverage reaches across the city and the research hubs and communities around it. The high density of academic medical centers and private research labs in the city drives a constant flow of early-stage breakthroughs. Access to venture capital and long-term lab space availability remain the primary factors that constrain how fast a project moves from bench to commercial scale.